| ABO |
P16442
|
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
|
Enzyme
|
|
0.427 |
0.885 |
| FSHMD1A |
|
facioscapulohumeral muscular dystrophy 1A
|
|
|
0.638 |
0.808 |
| GTS |
|
Gilles de la Tourette syndrome
|
|
|
0.682 |
0.615 |
| IFNA1 |
P01562
|
interferon alpha 1
|
|
|
0.371 |
0.923 |
| IFNA13 |
P01562
|
interferon alpha 13
|
|
|
0.374 |
0.923 |
| IGHG3 |
P01860
|
immunoglobulin heavy constant gamma 3 (G3m marker)
|
|
|
0.513 |
0.769 |
| COX1 |
P00395
|
cytochrome c oxidase subunit I
|
Enzyme
|
|
0.441 |
0.885 |
| COX2 |
P00403
|
cytochrome c oxidase subunit II
|
Enzyme
|
|
0.352 |
0.962 |
| ST2 |
|
suppression of tumorigenicity 2
|
|
|
0.576 |
0.692 |
| TRBV20OR9-2 |
|
T cell receptor beta variable 20/OR9-2 (non-functional)
|
|
|
0.403 |
0.923 |
| TAM |
|
Myeloproliferative syndrome, transient (transient abnormal
|
|
|
0.528 |
0.731 |
| H4C14 |
P62805
|
H4 clustered histone 14
|
|
|
0.541 |
0.692 |
| MBL3P |
|
mannose-binding lectin family member 3, pseudogene
|
|
|
0.518 |
0.769 |
| TUG1 |
|
taurine up-regulated 1
|
|
|
0.522 |
0.769 |
| MEG3 |
|
maternally expressed 3
|
|
|
0.471 |
0.846 |
| GAS5 |
|
growth arrest specific 5
|
|
|
0.497 |
0.808 |
| HSH2D |
Q96JZ2
|
hematopoietic SH2 domain containing
|
|
|
0.722 |
0.462 |
| PWAR1 |
|
Prader Willi/Angelman region RNA 1
|
|
|
0.490 |
0.769 |
| COPD |
|
Pulmonary disease, chronic obstructive, severe early-onset
|
|
|
0.456 |
0.885 |
| NEAT1 |
|
nuclear paraspeckle assembly transcript 1
|
|
|
0.502 |
0.769 |
| IRGM |
A1A4Y4
|
immunity related GTPase M
|
|
|
0.617 |
0.538 |
| MALAT1 |
|
metastasis associated lung adenocarcinoma transcript 1
|
|
|
0.435 |
0.846 |
| MIR122 |
|
microRNA 122
|
|
|
0.468 |
0.808 |
| MIR125A |
|
microRNA 125a
|
|
|
0.480 |
0.769 |
| MIR126 |
|
microRNA 126
|
|
|
0.447 |
0.846 |